Sleep plays a critical role in homeostasis of the body and mind. Insomnia is a disease that causes disturbances in the initiation and maintenance of sleep. Insomnia is known to affect not only the sleep process itself but also an individual’s cognitive function and emotional regulation during the daytime. It increases the risk of various neuropsychiatric diseases such as depression, anxiety disorder, and dementia. Although it might appear that insomnia only affects the nervous system, it is also a systemic disease that affects several aspects of the body, such as the cardiovascular, endocrine, and immune systems; therefore, it increases the risk of various diseases such as hypertension, diabetes mellitus, and infection. Insomnia has a wide range of effects on our bodies because sleep is a complex and active process. However, a high proportion of patients with insomnia do not seek treatment, which results in high direct and indirect costs. This is attributed to the disregard of many of the negative effects of insomnia. Therefore, we expect that understanding insomnia as a systemic disease will provide an opportunity to understand the condition better and help prevent secondary impairment due to insomnia.
Citations
Citations to this article as recorded by
Medical service utilization patterns among adults with insomnia: A retrospective cohort study Min Kyung Hyun, Jang Won Lee European Journal of Integrative Medicine.2024; 67: 102325. CrossRef
Socio-Ecological Context of Sleep: Gender Differences and Couples’ Relationships as Exemplars Andrea N. Decker, Alexandra R. Fischer, Heather E. Gunn Current Psychiatry Reports.2022; 24(12): 831. CrossRef
Clinical Spectrum and Trajectory of Innovative Therapeutic Interventions for Insomnia: A Perspective Yun-Jo Lo, Viraj Krishna Mishra, Hung-Yao Lo, Navneet Kumar Dubey, Wen-Cheng Lo Aging and disease.2022;[Epub] CrossRef
Understanding sleep and sleep disturbances in autism spectrum disorder, and management of insomnia: an update Hye-Geum Kim Yeungnam University Journal of Medicine.2021; 38(4): 265. CrossRef
The objectives of this study were to evaluate the effect of methylphenidate on attention deficit hyperactivity disorder (ADHD) and the comorbidity of the disorder, using child attention problem checklist to .56 (male : 38, female : 18) patients from. March 992 to February 1993. The results were as follows: Among 56 subjects, ADHD alone were 20 (335.71%) subjects, and with one additional diagnosis were 31 (55.35%) subjects and with two additional diagnosis were 5 (8.93%) subjects. There was significant improvement on symptoms in the scores rated by teachers in 7th and 28th day after mentylphenidate administration compared to baseline score (P<0.05) and 28th day score showed significant improvement compared to. 7th day score (P<0.05) and 28th day score showed significant improvement compared to 7th day score (P<0.05). There was significant improvment on symptoms in the scores rated by parents in 28th day after methylphenidate administration improvement compared with 7th day score. In single administration of methylphenidate in Sunday morning score compared to afternoon score (P<0.05). In the administration of significant improvement on symptoms compared with the Sunday morning rating score of parents (P<0.05) and the 28th day comparison was also showed significant improvement on symptoms in the scores rated by teachers compared with the scores rated by parents on symptoms (P<0.05). Among group comparison, all groups showed significant improvements (P<0.05) except conduct disorder & oppositional defiant group.